感染和疫苗免疫中潜在的新型冠状病毒2型保护性免疫相关因素。
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.
作者信息
Sui Yongjun, Bekele Yonas, Berzofsky Jay A
机构信息
Vaccine Branch, Center of for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
出版信息
Pathogens. 2021 Jan 30;10(2):138. doi: 10.3390/pathogens10020138.
Abstract
Both SARS-CoV-2 infections and vaccines induce robust immune responses. Current data suggested that high neutralizing antibody titers with sustained Th1 responses might correlate with protection against viral transmission and disease development and severity. In addition, genetic and innate immune factors, including higher levels of type I interferons, as well as the induction of trained immunity and local mucosal immunity also contribute to lower risk of infection and amelioration of disease severity. The identification of immune correlates of protection will facilitate the development of effective vaccines and therapeutics strategies.
摘要
新型冠状病毒2型（SARS-CoV-2）感染和疫苗均可诱导强烈的免疫反应。目前的数据表明，具有持续Th1反应的高中和抗体滴度可能与预防病毒传播、疾病发展及严重程度相关。此外，遗传和先天免疫因素，包括较高水平的I型干扰素，以及训练有素的免疫和局部黏膜免疫的诱导，也有助于降低感染风险和减轻疾病严重程度。确定保护性免疫相关因素将有助于开发有效的疫苗和治疗策略。
相似文献
1
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.
Pathogens. 2021 Jan 30;10(2):138. doi: 10.3390/pathogens10020138.
2
Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02076-16. Print 2017 May 15.
3
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
J Virol. 2020 Nov 23;94(24). doi: 10.1128/JVI.01176-20.
4
Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02257-16. Print 2017 May 1.
5
[The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
Mol Biol (Mosk). 2020 Nov-Dec;54(6):922-938. doi: 10.31857/S0026898420060154.
6
Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Viral Immunol. 2016 Jun;29(5):288-95. doi: 10.1089/vim.2015.0110.
7
Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.
J Transl Med. 2020 May 12;18(1):196. doi: 10.1186/s12967-020-02363-3.
8
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.
9
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Sci Adv. 2021 Feb 5;7(6). doi: 10.1126/sciadv.abe5819. Print 2021 Feb.
10
Could "trained immunity" be induced by live attenuated vaccines protect against COVID-19? Review of available evidence.
J Infect Dev Ctries. 2020 Sep 30;14(9):957-962. doi: 10.3855/jidc.12805.
引用本文的文献
1
COVID-19 Vaccination and Infection: Effect on Maternal and Cord Blood Antibody Levels at Delivery.
J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):262-268. doi: 10.1007/s13224-024-01960-2. Epub 2024 May 22.
2
COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan.
Clin Exp Med. 2024 Jun 10;24(1):123. doi: 10.1007/s10238-024-01388-y.
3
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.
Front Immunol. 2024 May 21;15:1386243. doi: 10.3389/fimmu.2024.1386243. eCollection 2024.
4
A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.
PLoS One. 2024 May 31;19(5):e0304534. doi: 10.1371/journal.pone.0304534. eCollection 2024.
5
Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.
J Allergy Clin Immunol. 2024 Feb;153(2):503-512. doi: 10.1016/j.jaci.2023.10.012. Epub 2023 Oct 28.
6
Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in .
Vaccine X. 2024 Jan 20;16:100443. doi: 10.1016/j.jvacx.2024.100443. eCollection 2024 Jan.
7
Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.
Cell Rep Methods. 2023 Aug 22;3(8):100565. doi: 10.1016/j.crmeth.2023.100565. eCollection 2023 Aug 28.
8
RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples.
Antibodies (Basel). 2023 Jun 16;12(2):39. doi: 10.3390/antib12020039.
9
A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response.
Vaccines (Basel). 2023 Apr 12;11(4):832. doi: 10.3390/vaccines11040832.
10
Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters.
Front Immunol. 2023 Mar 21;14:1138629. doi: 10.3389/fimmu.2023.1138629. eCollection 2023.
本文引用的文献
1
Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients.
Ann Intensive Care. 2021 Jan 13;11(1):9. doi: 10.1186/s13613-020-00798-x.
2
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Genetic mechanisms of critical illness in COVID-19.
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
5
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
6
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
7
Correlates of protection against SARS-CoV-2 in rhesus macaques.
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
8
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
9
Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France.
Emerg Infect Dis. 2021 Jan;27(1):113-21. doi: 10.3201/eid2701.203611. Epub 2020 Dec 1.
10
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
Zotero 插件